|
Published by: Global Markets Direct
Published: Nov. 28, 2012 - 66 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Grass Pollen Allergy Overview
- Therapeutics Development
- An Overview of Pipeline Products for Grass Pollen Allergy
- Grass Pollen Allergy Therapeutics under Development by Companies
- Grass Pollen Allergy Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Grass Pollen Allergy Therapeutics – Products under Development by Companies
- Grass Pollen Allergy Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Grass Pollen Allergy Therapeutics Development
- ALK-Abello A/S
- Allergy Therapeutics plc
- Circassia Holdings Ltd.
- Laboratorios LETI S.L.
- ANERGIS SA
- Bial - Portela & Ca, S.A.
- Biomay AG
- Grass Pollen Allergy – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- MPL-Based Sublingual Allergy Vaccines - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pollinex Quattro Grass - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pollinex Quattro Grass - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Allergen Extract Of Phleum Pratense - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ToleroMune Grass Allergy T-cell Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grazax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grazax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Phleum Pratense - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- gpASIT + TM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Epicutaneous Allergen Patch - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Pollen Allergen B-Cell Peptide Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Allergen RNA Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BM-32 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Allergen Specific IgG - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Hypoallergenic Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AllerG - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BIA-14-2954 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Grass Pollen Allergy Therapeutics – Drug Profile Updates
- Grass Pollen Allergy Therapeutics - Dormant Products
- Grass Pollen Allergy – Product Development Milestones
- Featured News & Press Releases
- Oct 23, 2012: ALK Announces North American Phase III Trial With Grass Allergy Immunotherapy Tablet Meets Primary Endpoint
- Aug 03, 2012: FDA Lifts Clinical Hold On Allergy Therapeutics's Grass Pollen Allergy Vaccine
- Jun 14, 2012: Biomay Reports Promising Results From Phase IIa Trial Of Allergy Vaccine
- Mar 02, 2012: ALK Publishes Landmark Results Showing Long-Term Disease Modifying Effect Of GRAZAX In American Journal Of Allergy And Clinical Immunology
- Jan 19, 2012: Circassia Receives European Patent For Grass Allergy T-Cell Vaccine
- Oct 25, 2011: Biomay Initiates Phase II Trial Of Grass Pollen Allergy Vaccine BM32
- Apr 18, 2011: ALK To Receive GRAZAX Reimbursement In Denmark
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Grass Pollen Allergy, H2 2012
- Products under Development for Grass Pollen Allergy – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- ALK-Abello A/S, H2 2012
- Allergy Therapeutics plc, H2 2012
- Circassia Holdings Ltd., H2 2012
- Laboratorios LETI S.L., H2 2012
- ANERGIS SA, H2 2012
- Bial - Portela & Ca, S.A., H2 2012
- Biomay AG, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Grass Pollen Allergy Therapeutics – Drug Profile Updates
- Grass Pollen Allergy Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Grass Pollen Allergy, H2 2012
- Products under Development for Grass Pollen Allergy – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractGrass Pollen Allergy – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Grass Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Grass Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy. Grass Pollen Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Grass Pollen Allergy.
- A review of the Grass Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Grass Pollen Allergy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
